🇺🇸 FDA

Intelligence Platform

Patents

Browse 38 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12240816

Deuterated compounds and uses thereof

Aldeyra Therapeutics, Inc. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128013

Toxic aldehyde related diseases and treatment

Aldeyra Therapeutics, Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12097188

Compositions and methods for the treatment of macular degeneration

Aldeyra Therapeutics, Inc. · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12064516

Pharmaceutical formulations and uses thereof

Aldeyra Therapeutics, Inc. · Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12029735

Polymorphic compounds and uses thereof

Aldeyra Therapeutics, Inc. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12005061

Ophthalmic formulations of methotrexate

Aldeyra Therapeutics, Inc. · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12006298

Polymorphic compounds and uses thereof

Aldeyra Therapeutics, Inc. · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12005060

Ophthalmic formulations of methotrexate

Aldeyra Therapeutics, Inc. · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11911385

Methotrexate treatment methods

Aldeyra Therapeutics, Inc. · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845722

Deuterated compounds and uses thereof

Aldeyra Therapeutics, Inc. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786518

Ophthalmic formulations and uses thereof

Aldeyra Therapeutics, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11771664

Toxic aldehyde related diseases and treatment

Aldeyra Therapeutics, Inc. · Granted Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11724987

Compositions and methods of treating retinal disease

Aldeyra Therapeutics, Inc. · Granted Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11701331

Toxic aldehyde related diseases and treatment

Aldeyra Therapeutics, Inc. · Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11583529

Treatment of inflammatory disorders

Aldeyra Therapeutics, Inc. · Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11459300

Deuterated compounds and uses thereof

Aldeyra Therapeutics, Inc. · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11312692

Polymorphic compounds and uses thereof

Aldeyra Therapeutics, Inc. · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11197821

Formulations for treatment of dry eye disease

Aldeyra Therapeutics, Inc. · Granted Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11129823

Combination treatment of ocular inflammatory disorders and diseases

Aldeyra Therapeutics, Inc. · Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11046650

Deuterated compounds and uses thereof

Aldeyra Therapeutics, Inc. · Granted Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11040039

Treatment of inflammatory disorders

Aldeyra Therapeutics, Inc. · Granted Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11007157

Toxic aldehyde related diseases and treatment

Aldeyra Therapeutics, Inc. · Granted Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10913722

Compositions and methods of treating retinal disease

Aldeyra Therapeutics, Inc. · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10588874

Toxic aldehyde related diseases and treatment

Aldeyra Therapeutics, Inc. · Granted Tue Mar 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted